Pyridostigmine improved the COMPASS-31 score by 43% and increased daily step count from 4000 to 7500 in a patient with postural orthostatic tachycardia syndrome.
Does pyridostigmine improve autonomic symptom burden and daily step count in a patient with POTS and genetic variants in acetylcholine processing?
Pyridostigmine significantly improved autonomic symptom burden and physical activity in a POTS patient with genetic variants in acetylcholine processing, suggesting a potential role for personalized, genotype-guided therapy.
Absolute Event Rate: 0% vs 0%
Abstract Background Postural orthostatic tachycardia syndrome (POTS) is a common autonomic disorder of heterogeneous pathophysiology involving relative sympathetic overactivity and/or parasympathetic hypofunction. POTS is characterized by exaggerated postural tachycardia in the absence of orthostatic hypotension, orthostatic intolerance and other cardiovascular and neurologic features. Case Summary We report a 30-year-old woman with POTS who experienced significant improvement with pyridostigmine. The whole genome sequencing demonstrated four single nucleotide polymorphisms - AchE, BChE, PEMT and CHDH - variants involved in acetylcholine processing that may have led to acetylcholine deficiency and resultant parasympathetic hypofunction with relative sympathetic hyperactivity in this patient. Her Composite Autonomic Symptom Score-31 (COMPASS-31) after initiation of pyridostigmine decreased from 56.15 pre-treatment to 32 post-treatment, which indicated a 43% improvement in autonomic symptom burden, while her daily step count increased from an average of 4000 steps pre- to 7500 steps post-treatment with pyridostigmine. Discussion We hypothesize that genetic variants in acetylcholine processing may result in acetylcholine deficiency state and may represent one of many pathophysiologic mechanisms of POTS. Whole genome sequencing and validated genetic tests for these and other genetic variants may be valuable diagnostic tools in delineating specific pathophysiology, POTS phenotypes and personalized treatment approaches.
Stephenson et al. (Wed,) reported a other. Pyridostigmine improved the COMPASS-31 score by 43% and increased daily step count from 4000 to 7500 in a patient with postural orthostatic tachycardia syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: